强直性脊柱炎患者在白细胞介素17抑制剂治疗期间的葡萄膜炎病程

IF 0.8 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Doklady Biochemistry and Biophysics Pub Date : 2024-06-10 DOI:10.1134/S1607672924700868

A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova

{"title":"强直性脊柱炎患者在白细胞介素17抑制剂治疗期间的葡萄膜炎病程","authors":"A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova","doi":"10.1134/S1607672924700868","DOIUrl":null,"url":null,"abstract":"Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), p = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), p = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), p = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), p = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy\",\"authors\":\"A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova\",\"doi\":\"10.1134/S1607672924700868\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), p = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), p = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), p = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), p = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.\",\"PeriodicalId\":529,\"journal\":{\"name\":\"Doklady Biochemistry and Biophysics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Doklady Biochemistry and Biophysics\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://link.springer.com/article/10.1134/S1607672924700868\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Doklady Biochemistry and Biophysics","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1134/S1607672924700868","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

生物改良抗风湿药（bDMARDs）对强直性脊柱炎（AS）的各种临床表现有不同的影响。有关白细胞介素17抑制剂（IL17-i）对强直性脊柱炎葡萄膜炎影响的数据仍在不断积累。目的：评估IL17-i疗法对强直性脊柱炎葡萄膜炎病程的影响。研究涉及73名强直性脊柱炎患者（纽约标准，1984年），他们接受IL17-i（57-secukinumab (SEC)，22-netakimab (NTK)）治疗至少1年。患者纳入研究时的平均年龄为（41.93±8.95）岁，强直性脊柱炎的平均病程为（10.75±6.22）年。患者中有 40 名男性（56.7%）和 33 名女性（43.3%）。62/73（85%）例患者检测到 HLA-B27，58（79%）例患者患有髋关节炎，63（86.3%）例患者患有腱鞘炎，57（78%）例患者患有外周关节炎，7（9.5%）例患者患有银屑病，3（4.1%）例患者患有炎症性肠病（IBD）；6（8.2%）例患者在 16 岁前开始患病；19（26%）例患者在患病期间至少发作过一次葡萄膜炎。葡萄膜炎的发病率是通过比较开始使用 bDMARDs 治疗前和使用 IL17-i 期间每 100 患者年的发病次数估算得出的。在开始使用bDMARDs治疗前，所有患者的葡萄膜炎发病率为每100 pt-年8.3例（95% CI 0.065-0.107），在使用IL17-i治疗期间为每100 pt-年9.2例（95% CI 0.06-0.15），P = 0.72。在开始使用bDMARDs治疗前，使用SEC的患者葡萄膜炎发病率为每100 pt-年10.1例（95% CI 0.079-0.13），在SEC治疗期间为每100 pt-年9.4例（95% CI 0.05-0.15），P = 0.74。使用NTK的患者葡萄膜炎发病率在开始使用bDMARDs治疗前为每100 pt-年4.8例（95% CI 0.028-0.08），在NTK治疗期间为每100 pt-年7.1例（95% CI 0.019-022），p = 0.3。对于有葡萄膜炎病史的患者，在开始使用bDMARDs治疗前，葡萄膜炎的发生率为每100 pt-年22.5例（95% CI 0.18-0.28），在IL17-i治疗期间，葡萄膜炎的发生率为每100 pt-年29.1例（95% CI 0.18-0.43），p = 0.29。在 SEC 治疗期间，57 例患者中有 4 例（7%）出现葡萄膜炎；在 NTK 治疗期间，25 例患者中有 1 例（4%）出现葡萄膜炎。在使用 SEC 治疗期间，记录到一例新发葡萄膜炎。与非生物疗法相比，IL17-i疗法的葡萄膜炎发病率没有明显差异。在研究组中，IL17-i疗法对强直性脊柱炎葡萄膜炎的病程没有明显影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy

查看原文本刊更多论文

Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy

Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), p = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), p = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), p = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), p = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Doklady Biochemistry and Biophysics 生物-生化与分子生物学

CiteScore

1.60

自引率

12.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Doklady Biochemistry and Biophysics is a journal consisting of English translations of articles published in Russian in biochemistry and biophysics sections of the Russian-language journal Doklady Akademii Nauk. The journal''s goal is to publish the most significant new research in biochemistry and biophysics carried out in Russia today or in collaboration with Russian authors. The journal accepts only articles in the Russian language that are submitted or recommended by acting Russian or foreign members of the Russian Academy of Sciences. The journal does not accept direct submissions in English.